Abstract
An activating mutation (V617F) in the pseudokinase domain of the Janus kinase (JAK)-2 tyrosine kinase has been described in 90% of patients with polycythemia vera (PV) and 50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (MF). The discovery of JAK2V617F stirred the development of JAK2 inhibitors for treatment of patients with MF, ET and PV. Similar to other tyrosine kinase (TK) inhibitors in current use, JAK2 inhibitors target the adenosine triphosphate (ATP) binding site at the TK domain and not the pseudokinase domain, thus affecting both mutated and wild-type kinases. In fact, clinical trials of these compounds have demonstrated improvements in constitutional symptoms and splenomegaly in patients with both mutated and wild-type JAK2 MF. It is believed that these drugs may act not only through inhibition of neoplastic cell proliferation, but also by downregulating signaling through proinflammatory cytokine receptors. In this article, we review the current state of JAK2 inhibitors and discuss why these drugs could be a valuable addition to the treatment armamentarium for patients with and without the JAK2V617F mutation.
Keywords: Essential thrombocythemia, JAK2 inhibitor, JAK2V617F, Myelofibrosis, Polycythemia vera, CYTOKINE RECEPTORS, JAK TYROSINE KINASES, proinflammatory state, erythropoietin, microenvironmental cells
Anti-Cancer Agents in Medicinal Chemistry
Title:JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Volume: 12 Issue: 9
Author(s): Fabio P. S. Santos and Srdan Verstovsek
Affiliation:
Keywords: Essential thrombocythemia, JAK2 inhibitor, JAK2V617F, Myelofibrosis, Polycythemia vera, CYTOKINE RECEPTORS, JAK TYROSINE KINASES, proinflammatory state, erythropoietin, microenvironmental cells
Abstract: An activating mutation (V617F) in the pseudokinase domain of the Janus kinase (JAK)-2 tyrosine kinase has been described in 90% of patients with polycythemia vera (PV) and 50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (MF). The discovery of JAK2V617F stirred the development of JAK2 inhibitors for treatment of patients with MF, ET and PV. Similar to other tyrosine kinase (TK) inhibitors in current use, JAK2 inhibitors target the adenosine triphosphate (ATP) binding site at the TK domain and not the pseudokinase domain, thus affecting both mutated and wild-type kinases. In fact, clinical trials of these compounds have demonstrated improvements in constitutional symptoms and splenomegaly in patients with both mutated and wild-type JAK2 MF. It is believed that these drugs may act not only through inhibition of neoplastic cell proliferation, but also by downregulating signaling through proinflammatory cytokine receptors. In this article, we review the current state of JAK2 inhibitors and discuss why these drugs could be a valuable addition to the treatment armamentarium for patients with and without the JAK2V617F mutation.
Export Options
About this article
Cite this article as:
P. S. Santos Fabio and Verstovsek Srdan, JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (9) . https://dx.doi.org/10.2174/187152012803529727
DOI https://dx.doi.org/10.2174/187152012803529727 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia
Reviews on Recent Clinical Trials A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Homeostasis and Compensatory Homeostasis: Bridging Western Medicine and Traditional Chinese Medicine
Current Cardiology Reviews TNFα as Therapeutic Target: New Drugs, More Applications
Current Drug Targets - Inflammation & Allergy Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Editorial [Hot Topic: Pain - Unmet Need and Emerging Targets & Therapies (Guest Editor: Sivaram Pillarisetti)]
CNS & Neurological Disorders - Drug Targets Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Adverse Drug Reactions in Hospitals: A Narrative Review
Current Drug Safety A Comprehensive Systemic Literature Review of Pericardial Decompression Syndrome: Often Unrecognized and Potentially Fatal Syndrome
Current Cardiology Reviews An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Tachykinins and the Cardiovascular System
Current Drug Targets Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox
Current Vascular Pharmacology Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology